All In Biotech

Drug Trial Radar · NCT03315455

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients

Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

85

Actual

Start

Apr 26, 2018

Primary completion

Aug 3, 2022

Study completion Aug 29, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, open-label, Phase 3 study with randomized and non-randomized arms is designed to investigate the efficacy, safety, and pharmacokinetics of emicizumab in participants with hemophilia A regardless of factor VIII (FVIII) inhibitor status. Participants greater than or equal to (≥)12 years old who received episodic therapy with FVIII or bypassing agents prior to study entry and experienced at least 5 bleeds over the prior 24 weeks will be randomized in a 2:2:1 ratio to the following regimens: Arm A: Emicizumab prophylaxis at 3 milligrams per kilogram (mg/kg) once every week (QW) subcutaneously (SC) for 4 weeks, followed by 1.5 mg/kg QW SC; Arm B: Emicizumab prophylaxis at 3 mg/kg QW SC for 4 weeks, followed by 6 mg/kg once every 4 weeks (Q4W) SC; and Arm C: No prophylaxis (control arm). In addition, pediatric participants less than (\<)12 years old with hemophilia A and FVIII inhibitors who received episodic therapy with bypassing agents prior to study entry will be enrolled to Arm D: Emicizumab prophylaxis at 3 mg/kg QW SC for 4 weeks, followed by 1.5 mg/kg QW SC.

Conditions

  • Hemophilia A

Interventions

  • EmicizumabDrug

    Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Model-Based Annualized Bleeding Rate for Treated BleedsTime frame: From Baseline to at least 24 weeks
  2. Mean Calculated Annualized Bleeding Rate for Treated BleedsTime frame: From Baseline to at least 24 weeks
  3. Median Calculated Annualized Bleeding Rate for Treated BleedsTime frame: From Baseline to at least 24 weeks

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Xiangya Hospital of Centre-South University

    Changsha, China

  • Southern Medical University Nanfang Hospital

    Guangdong Province Guangzhou City, China

  • Ruijin Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Tianjin Institute of Hematology & Blood Diseases Hospital

    Tianjin, China

  • Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

    Wuhan, China

  • Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech

    Wuhan, China

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Prince of Wales Hospital

    Shatin, Hong Kong

  • Penang General Hospital

    George Town, Pulau Pinang, Malaysia

  • Queen Elizabeth Hospital

    Sabah, Sabah, Malaysia

  • Ramathibodi Hospital

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.